160 completed, 59 unknown, 46 recruiting, 34 terminated. 348 Phase 3, 65 Phase 2.
Follow Leukemia, Myeloid, Acute: new trials by email Literature Review of Leukemia, Myeloid, Acute trials Research Report on Leukemia, Myeloid, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy IPN60340 + azacitidine + venetoclax, Placebo + azacitidine + venetoclax - Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | Phase 2 / Phase 3 | Not yet recruiting | Ipsen | 540 | 2026-11-01 | 2026-09-10 |
| Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML Unrelated Umbilical Cord Blood Infusion, Standard consolidation chemotherapy with high-dose cytarabine - AML (Acute Myelogenous Leukemia) | Phase 3 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 132 | 2026-10-01 | 2026-08-12 |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Best Practice, Biospecimen Collection, Cytarabine - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 556 | 2026-08-14 | 2026-09-04 |
| Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse Lisaftoclax Plus Azacitidine - Acute Myeloid Leukemia (AML), Maintenance Treatment | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 191 | 2026-08-10 | 2026-07-07 |
| Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML Mitoxantrone Hydrochloride Liposome, Cytarabine, Granulocyte Colony-Stimulating Factor(G-CSF) - Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Not yet recruiting | Ruijin Hospital | 168 | 2026-07-30 | 2026-07-29 |
| Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) Azacitidine, Venetoclax, Quizartinib - Acute Myeloid Leukemia, Adult | Phase 3 | Recruiting | PETHEMA Foundation | 376 | 2026-07-02 | 2026-10-28 |
| Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients Lisaftoclax (APG-2575) - Acute Promyelocytic Leukemia (APL) | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 20 | 2026-07-01 | 2026-06-30 |
| A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Pivekimab Sunirine, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | AbbVie | 660 | 2026-06-30 | 2026-10-22 |
| Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA - Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia | Phase 3 | Recruiting | Quetzal Therapeutics | 150 | 2026-06-08 | 2026-10-30 |
| VABu Conditioning in Elderly AML HSCT VaBU - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML) | Phase 2 / Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 20 | 2026-05-07 | 2026-05-14 |
| MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib Gilteritinib, Sorafenib - Acute Myeloid Leukemia (AML), FLT3-ITD Mutation | Phase 3 | Recruiting | The First Affiliated Hospital of Soochow University | 594 | 2026-05-01 | 2026-03-20 |
| VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML Gilteritinib + Azacitidine + Venetoclax, Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib, Re-induction Therapy - AML, Adult | Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 300 | 2026-04-30 | 2026-03-25 |
| VAH vs VA in Newly Diagnosed Elderly AML Venetoclax, Azacitidine, Homoharringtonine - Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years) | Phase 3 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 308 | 2026-04-10 | 2026-04-13 |
| A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia BL-M11D1, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 216 | 2026-04-02 | 2026-09-10 |
| VEN+IDAC vs IDAC in AML Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia) | Phase 2 / Phase 3 | Enrolling by invitation | Guangdong Second Provincial General Hospital | 232 | 2026-04-01 | 2026-04-17 |
| DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML Arm A (VEN+"2+6"DA), Arm B (DEC3-VEN), Arm C ("3+7"DA) - AML (Acute Myeloid Leukemia) | Phase 3 | Recruiting | The Second Affiliated Hospital of Kunming Medical University | 291 | 2026-04-01 | 2026-07-20 |
| Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML Mitoxantrone Hydrochloride Liposome, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 204 | 2026-03-10 | 2026-03-20 |
| Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 267 | 2026-03-01 | 2026-06-16 |
| Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax | Phase 2 / Phase 3 | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 450 | 2026-03-01 | 2026-06-16 |
Showing 20 of 348. Sign in to see all of them.
Leukemia (76) · Myelodysplastic Syndromes (69) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (62) · Lymphoma, Non-Hodgkin (34) · Leukemia, Lymphocytic, Chronic, B-Cell (30) · Hodgkin Disease (29) · Congenital Abnormalities (28) · Lymphoma (26) · Lymphoma, Large B-Cell, Diffuse (26) · Lymphoma, Mantle-Cell (26) · Multiple Myeloma (26) · Burkitt Lymphoma (25) · Leukemia, Monocytic, Acute (25) · Leukemia, Myeloid, Accelerated Phase (25)
Hemic and Lymphatic Diseases (348) · Neoplasms by Histologic Type (348) · Hematologic Diseases (344) · Leukemia, Myeloid (344) · Neoplasms (331) · Leukemia (272) · Bone Marrow Diseases (106) · Pathological Conditions, Signs and Symptoms (73) · Pathologic Processes (72) · Immune System Diseases (71) · Immunoproliferative Disorders (68) · Lymphatic Diseases (68) · Leukemia, Lymphoid (65) · Lymphoproliferative Disorders (64) · Disease Attributes (63)
Cytarabine (110) · Azacitidine (57) · Daunorubicin (54) · venetoclax (41) · Idarubicin (36) · Cyclophosphamide (33) · Etoposide (29) · fludarabine (28) · Decitabine (27) · Busulfan (26) · Mitoxantrone (25) · Methotrexate (23) · Tretinoin (20) · Gemtuzumab (19) · Granulocyte Colony-Stimulating Factor (14)
The First Affiliated Hospital of Soochow University (17) · European Organisation for Research and Treatment of Cancer - EORTC (12) · Nanfang Hospital, Southern Medical University (10) · University of Ulm (9) · AbbVie (8) · Children's Oncology Group (8) · National Cancer Institute (NCI) (8) · Fred Hutchinson Cancer Center (6) · M.D. Anderson Cancer Center (6) · Stichting Hemato-Oncologie voor Volwassenen Nederland (6) · Acute Leukemia French Association (5) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (5) · Institute of Hematology & Blood Diseases Hospital, China (5) · St. Jude Children's Research Hospital (5) · Assistance Publique - Hôpitaux de Paris (4)
United States (143) · Germany (90) · France (87) · China (78) · Italy (66) · Spain (63) · Canada (54) · United Kingdom (53) · Belgium (50) · Australia (49) · Austria (43) · Poland (39) · Czechia (37) · South Korea (36) · Israel (34)
Qifa Liu (5) · Alan K. Burnett, MD, FRCP (3) · Depei Wu, M.D., Ph.D. (3) · Franco Mandelli, MD (2) · Guopan Yu (2) · Han Yue, Ph.D (2) · Hartmut Doehner, MD (2) · Jeffrey Taub, MD (2) · Mary Horowitz, MD (2) · Mary Horowitz, MD, MS (2)
PMID 37267439, PMID 22965967, PMID 31375516, PMID 36184192, PMID 37341189, PMID 19602710, PMID 20625116, PMID 21343560, PMID 21459791, PMID 22649106, PMID 23248249, PMID 23749683, PMID 23841729, PMID 24816240, PMID 25987659, PMID 29859851, PMID 29926156, PMID 30337300, PMID 30523055, PMID 34596937, PMID 35829925, PMID 36064577, PMID 36815378, PMID 37185873, PMID 37703506, PMID 38295280, PMID 40294366, PMID 40973764, PMID 42085603, PMID 42668697, PMID 10438706, PMID 12424199, PMID 15459300, PMID 15761020, PMID 16484584, PMID 16932345, PMID 16939487, PMID 16996130, PMID 17116939, PMID 17251531, PMID 17252021, PMID 17315155, PMID 17339189, PMID 17397698, PMID 18083847, PMID 18182574, PMID 18838471, PMID 19059939, PMID 19242495, PMID 19291085
2025 (7), 2014 (5), 2015 (5), 2016 (5), 2017 (4), 2023 (4), U10CA021115 (4), U10CA180886 (4), 2018 (3), U01HL069294 (3), U10CA031946 (3), U10CA032102 (3), U24CA076518 (3), P01CA018029 (2), U10CA098543 (2)